Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Long COVID, Long COVID Syndrome. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Mexico
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them. The hypothesis is that the expression of miR-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin B12 in serum in subjects suffering from long COVID with neurological symptoms of depression, anxiety and fatigue.
Primary outcome measures
- Change of microRNA expression between long COVID group and control group [Time frame: immediately after the blood extraction]
- Change of vitamin B12 concentration between long COVID group and control group [Time frame: immediately after the blood extraction]
- Link the expression of microRNAs with the score obtained in the instruments to evaluate depression, anxiety and fatigue [Time frame: immediately after the blood extraction]
- Link the concentration of vitamin B23 with the score obtained in the instruments to evaluate depression, anxiety and fatigue. [Time frame: immediately after the blood extraction]
Eligibility criteria
Inclusion criteria
- Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing.
- With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms.
Exclusion criteria
- Subjects who have presented symptoms of acute infection in the last twelve weeks.
- Subjects who present diagnostic premorbid neurological alterations.
- Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Mexico · 1 center
- Instituto Nacional de Rehabilitación — Mexico City
Identifiers
NCT: NCT06864156 · 03/24 AD 2025